0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Multispecialty Contralateral Study of Clinical Experience With the Ultratine Forehead Fixation Device: Evolution of the Original Endotine Device FREE

David B. Apfelberg, MD; James Newman, MD; Miles Graivier, MD; Mark A. Petroff, MD; Richard Levine, MD
Arch Facial Plast Surg. 2008;10(4):280-282. doi:10.1001/archfaci.10.4.280.
Text Size: A A A
Published online

Since the introduction of the Endotine forehead fixation device (Coapt Systems, Palo Alto, California) in March 2003, there has been widespread acceptance of the product. The device has been implanted in over 40 000 patients, and its safety and efficacy have been documented by numerous multispecialty clinical studies.17 Although the device has provided satisfactory elevation and fixation for endoscopic and open and coronal forehead-lifts, a small percentage of surgeons and patients have complained of problems related to persistent palpability and sensitivity owing to the 12- to 15-month absorption time of the biodegradable polymer.

The Ultratine forehead fixation device (Coapt) was cleared by the US Food and Drug Administration in 2006. It has the same dimensions as the original device, but the composition of the polymer has been altered to different percentages of polylactic acid and polyglycolic acid (PLA-PGA) designed for absorption and biodegradation starting at the 2- to 3-month interval.

In July 2006, a multispecialty contralateral study was undertaken comparing the original Endotine to the new Ultratine in a partially blinded contralateral study. The goal was to determine end user (surgeon and patient) satisfaction with the performance of the device. Twelve patients completed the study at 90 days, and physicians rated the overall performance as good or satisfactory at a 100% level.

The Ultratine forehead fixation device consists of a polymer blend altered to result in a softer material that loses biological strength after 2 to 3 months, 50% of its mass after 4 months, and 70% of its mass after 10 months. The dimensions of this device are identical to the original Endotine. It consists of a 0.5-mm-thick triangular platform containing 5 tines (tine length, 3.0-3.5 mm) and a bone peg (length, 3.75 mm) (Figure 1).

Place holder to copy figure label and caption
Figure 1.

The Ultratine device consists of a triangular platform with 5 tines and a bone peg for attachment to the outer table of the skull.

Graphic Jump Location

The device attaches to the skull by a peg on the bottom of the triangular platform that is press fitted into a 3.75-mm hole drilled into the outer cortex of the frontal bone. With experience, the device may be deployed in about 2 to 3 minutes per side. Both devices are based on the concept of multipoint fixation, in which the 5 tines act to distribute the forces of fixation and elevation over a diffuse area. Thus, no single point is carrying the entire force. This even distribution of force contrasts with the other commonly used methods of fixation employing sutures, in which the sharp edge of the suture acts almost like a scalpel, cutting through the periosteum and galea as the tissue swells during the postoperative period. As the sharp suture pulls through the tissue, there is a descent of several millimeters from the original elevation. Thus, the Endotine device has demonstrated the ability to elevate and fix the forehead in the original position achieved by the surgery without change or regression and redescent.

The Endotine and Ultratine devices provide mechanical fixation until biological fixation occurs (estimated, based on animal studies, at 6-8 weeks). Once the periosteum is firmly and permanently adhered to the outer table of the skull, the device is no longer necessary and subsequently biodegrades and absorbs at varying intervals. The Ultratine device softens and loses 90% of its strength in 60 days and 50% of its mass by 4 months. This rapid degradation after periosteal attachment means that the patient has less palpability and sensitivity after 60 days. The original Endotine loses only 37% of its strength in 60 days and has an absorption and biodegradability profile of 12 to 18 months.

The Endotine and Ultratine devices may also be used in open and coronal forehead-lift procedures. By fixing the anterior forehead flap solidly with the device, the amount of scalp necessary for resection is markedly decreased, and there is less tension on the closure, resulting in a smaller scar and less alopecia.

The study protocol required multispecialty surgeons to implant the Ultratine device in one side of the forehead and the Endotine in the contralateral side. Seventeen patients were enrolled; 12 patients completed the study at 90 days, and 5 patients were lost to follow-up. The follow-up visits were performed at 30 days and 90 days after surgery. Preoperative and postoperative photography was designed to provide identical clinical landmarks, and computerized digitized measurements were designed to measure heights of elevation from fixed points.

At each patient's 90-day follow-up visit, tissue elevation was maintained, and 100% of physicians were satisfied or very satisfied with the results from both devices. In addition, the performance of both devices was rated as good or excellent in 100% of the cases. For both devices, visibility was rated as not visible or slightly visible in 100% of cases. Device palpability was rated as not palpable or slightly palpable in 100% of cases for the Ultratine device and not palpable or slightly palpable in 83.3% of cases for the Endotine device. The 90-day sensitivity ratings for the Ultratine were markedly lower than for the Endotine. Physicians rated the overall performance satisfaction for the Ultratine as 100% (excellent/satisfactory/good) at the 90-day interval.

At 90 days, 100% of the patients were satisfied or very satisfied with the Ultratine device, but only 75% were satisfied with the Endotine. There was slight or no visibility in 100% of the patients with the Ultratine device and in only 91.7% of the patients with Endotine. There was slight or no palpability in 100% of the patients with the Ultratine device and in only 58.3% of those with the Endotine. Sensibility was markedly less in those with the Ultratine (Figure 2 and Figure 3).

Place holder to copy figure label and caption
Figure 2.

A 62-year-old female patient. A, Preoperative view. B, Postoperative view, 12 months after surgery, demonstrating satisfactory cosmetic effect and equal elevation and fixation of the forehead. The patient reported greater comfort on the Ultratine (left) side.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

A 57-year-old female patient. A, Preoperative view. B, Postoperative view, 90 days after surgery, demonstrating satisfactory cosmetic effect and equal elevation and fixation of the forehead. The patient reported greater comfort on the Ultratine (left) side.

Graphic Jump Location

In patients with the Ultratine device, by the 90-day follow-up visit, tissue elevation was maintained, the patient's sensitivity had decreased, and the device palpability and visibility had decreased. Overall, physicians rated the product performance satisfaction as 100% (excellent/satisfactory/good). The device exceeded all acceptance criteria set in the study protocol with a high level of patient satisfaction.

The Ultratine forehead fixation device contains a revised polymer concentration of PLA-PGA that results in a softer material at the 3-month interval and 70% bioabsorption in 10 months. Results in a series of 12 patients observed for 90 days indicate that all patients achieved secure and permanent fixation and elevation of their forehead-lifts without regression or redescent. Palpability, visibility, and sensitivity of the device were markedly diminished or absent by the 3- to 4-month interval. The Ultratine device represents an improved evolution over the original Endotine device. It is expected that further experience will result in a general acceptance of the Ultratine device in a wide variety of cases as a satisfactory replacement for the Endotine device.

ARTICLE INFORMATION

Correspondence: Dr Apfelberg, Department of Plastic Surgery, Stanford University Medical Center, 1426 Pitman Ave, Palo Alto, CA 94301 (dapfelberg@yahoo.com).

Financial Disclosure: Drs Apfelberg and Graivier are paid consultants to Coapt Systems and receive stock and financial support. Drs Newman and Graivier are members of the Coapt Systems physician advisory board.

Stevens  WGApfelberg  DBStoker  DASchantz  SA The Endotine: a new biodegradable fixation device for endoscopic forehead lifts. Aesthetic Surg J 2003;23103- 107
Link to Article
Holzapfel  AMMangat  DS Endoscopic forehead-lift using a bioabsorbable fixation device. Arch Facial Plast Surg 2004;6 (6) 389- 393
PubMed Link to Article
Berkowitz  RLJacobs  DIGorman  PJ Brow fixation with the Endotine device in endoscopic brow lift. Plast Reconstr Surg 2005;116 (6) 1761- 1764
PubMed Link to Article
Saltz  A Endoscopic temporal-incision only midface lift is enhanced by Endotine technique. Aesthetic Surg J 2005;2580- 83
Link to Article
Chowdhury  SMalhotra  RSmith  R The Endotine forehead device for brow and forehead lift. Ophthal Plast Reconstr Surg 2007;23 (5) 358- 362
PubMed Link to Article
Boehmler  JHJudson  BLDavison  SP Reconstructive application of the Endotine suspension device. Arch Facial Plast Surg 2007;9 (5) 328- 332
PubMed Link to Article
Byrne  PJ Efficacy and safety of Endotine fixation device in endoscopic brow-lift. Arch Facial Plast Surg 2007;9 (3) 212- 214
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

The Ultratine device consists of a triangular platform with 5 tines and a bone peg for attachment to the outer table of the skull.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

A 62-year-old female patient. A, Preoperative view. B, Postoperative view, 12 months after surgery, demonstrating satisfactory cosmetic effect and equal elevation and fixation of the forehead. The patient reported greater comfort on the Ultratine (left) side.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

A 57-year-old female patient. A, Preoperative view. B, Postoperative view, 90 days after surgery, demonstrating satisfactory cosmetic effect and equal elevation and fixation of the forehead. The patient reported greater comfort on the Ultratine (left) side.

Graphic Jump Location

Tables

References

Stevens  WGApfelberg  DBStoker  DASchantz  SA The Endotine: a new biodegradable fixation device for endoscopic forehead lifts. Aesthetic Surg J 2003;23103- 107
Link to Article
Holzapfel  AMMangat  DS Endoscopic forehead-lift using a bioabsorbable fixation device. Arch Facial Plast Surg 2004;6 (6) 389- 393
PubMed Link to Article
Berkowitz  RLJacobs  DIGorman  PJ Brow fixation with the Endotine device in endoscopic brow lift. Plast Reconstr Surg 2005;116 (6) 1761- 1764
PubMed Link to Article
Saltz  A Endoscopic temporal-incision only midface lift is enhanced by Endotine technique. Aesthetic Surg J 2005;2580- 83
Link to Article
Chowdhury  SMalhotra  RSmith  R The Endotine forehead device for brow and forehead lift. Ophthal Plast Reconstr Surg 2007;23 (5) 358- 362
PubMed Link to Article
Boehmler  JHJudson  BLDavison  SP Reconstructive application of the Endotine suspension device. Arch Facial Plast Surg 2007;9 (5) 328- 332
PubMed Link to Article
Byrne  PJ Efficacy and safety of Endotine fixation device in endoscopic brow-lift. Arch Facial Plast Surg 2007;9 (3) 212- 214
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

795 Views
4 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs